Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

Histone deacetylase inhibitors (HDACi) and agents such as recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic anti-TRAIL receptor (TRAIL-R) antibodies are anticancer agents that have shown promise in preclinical settings and in early phase clinical trials as mon...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Frew, Ailsa J., Lindemann, Ralph K., Martin, Ben P., Clarke, Christopher J. P., Sharkey, Janelle, Anthony, Desiree A., Banks, Kellie-Marie, Haynes, Nicole M., Gangatirkar, Pradnya, Stanley, Kym, Bolden, Jessica E., Takeda, Kazuyoshi, Yagita, Hideo, Secrist, J. Paul, Smyth, Mark J., Johnstone, Ricky W.
Formato: Artigo
Idioma:Inglês
Publicado: National Academy of Sciences 2008
Assuntos:
Biological Sciences
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2516269/
https://ncbi.nlm.nih.gov/pubmed/18685088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0801868105
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares